Mechanism of lethal proarrhythmia observed in the cardiac arrhythmia suppression trial: Role of adrenergic modulation of drug binding

PACE - Pacing and Clinical Electrophysiology

Volumn 20, Issue 2 II, 1997, Pages 455-467

  Packer, Douglas L ^a,b   Munger, Thomas M ^a   Johnson, Susan B ^a   Cragun, Kevin T ^a  

^a MAYO CLINIC   (United States)

^b ST MARY S HOSPITAL   (United States)

Author keywords

antiarrhythmic drugs; flecainide; myocardial infarction; proarrhythmia; sudden cardiac death; ventricular arrhythmia; ventricular tachycardia

Indexed keywords

FLECAINIDE;

ACUTE HEART INFARCTION; ANISOTROPY; ARRHYTHMOGENESIS; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CELL MEMBRANE DEPOLARIZATION; DRUG EFFECT; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; SUDDEN DEATH;

ANIMALS; ARRHYTHMIA; FLECAINIDE; HEART CONDUCTION SYSTEM; HUMANS; MYOCARDIAL INFARCTION;

EID: 0031043534     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1997.tb06204.x     Document Type: Article

References (78)

1. Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986; 58:1151-1160.
2. Moss AJ, Davis HT, DeCamilla J, et al. Ventricular ectopic beats and their relation to sudden and non-sudden cardiac death after myocardial infarction. Circulation 1979; 60:998-1003.
3. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 1977; 297: 750-757.
4. Hine LK, Laird NM, Hewitt P, et al. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989; 262: 3037-3040.
5. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412.
6. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233.
7. Anderson J, Platia E, Hallstrom A, et al. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction: A possible explanation for increased mortality in the cardiac arrhythmia suppression trial (CAST). Circulation 1994; 90:2843-2852.
8. Cannom DS, Levy W, Cohen LS. The short- and long-term prognosis of patients with transmural and nontransmural myocardial infarction. Am J Med 1976; 61:452-458.
9. Hutter AM Jr, DeSanctis RW, Flynn T, et al. Non-transmural myocardial infarction: A comparison of hospital and late clinical course in patients with that of matched patients with transmural anterior and transmural inferior myocardial infarction. Am J Cardiol 1981; 48:595-602.
10. Krone RJ, Friedman E, Rhanavero S, et al. Long-term prognosis after first Q-wave (transmural) or non-Q-wave (nontransmural) myocardial infarction: Analysis of 593 patients. Am J Cardiol 1983; 52:234-239.
11. max in guinea pig ventricular myocardium. Circ Res 1982; 50:210-217.
12. Nattel S, Elharrar V, Zipes DP, et al. pH-dependent electrophysiological effects of quinidine and lidocaine on canine cardiac Purkinje fibers. Circ Res 1981; 48:55-61.
13. Hille B. The pH-dependent rate of action of local anesthetics on the node of Ranvier. J Gen Physiol 1977; 69:475-496.
14. max in guinea pig myocardium. Circ Res 1985; 56: 696-703.
15. Nattel S, Pedersen DH, Zipes DP. Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovascular Research 1981; 15:80-85.
16. Kou WH, Nelson SD, Lynch JJ, et al. Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: Evaluation in a conscious canine model of sudden death. J Am Coll Cardiol 1987; 9:359-365.
17. Wilber DJ, Lynch JJ, Montgomery D, et al. Postinfarction sudden death: Significance of inducible ventricular tachycardia and infarct size in a conscious canine model. Am Heart J 1985; 109:8-18.
18. Restivo M, Yin H, Caref B, et al. Reentrant arrhythmias in the subacute infarction period: The proarrhythmic effect of flecainide acetate on functional reentrant circuits. Circulation 1995; 91: 1236-1246.
19. Ranger S, Nattel S. Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation 1995; 92:1300-1311.
20. Coromilas J, Saltman AE, Waldecker B, et al. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Circulation 1995; 91:2245-2263.
21. Brugada J, Boersma L, Kirchhof C, et al. Proarrhythmic effects of flecainide: Experimental evidence for increased susceptibility to reentrant arrhythmias. Circulation 1991; 84:1808-1818.
22. Spach M. The discontinuous nature of electrical propagation in cardiac muscle: Consideration of a quantitative model incorporating the membrane ionic properties and structural complexities. Ann Biomed Eng 1983; 11:209-261.
23. Anderson KP, Walker R, Lux RL, et al. Conduction velocity depression and drug-induced ventricular tachyarrhythmias: Effects of lidocaine in the intact canine heart. Circulation 1990; 81:1024-1038.
24. Kadish AH, Spear JF, Levine JH, et al. The effects of procainamide on conduction in anisotropic canine ventricular myocardium. Circulation 1986; 74:616-625.
25. Arnsdorf MF, Sawicki GJ. Flecainide and the electrophysiologic matrix: The electrophysiologic effects of flecainide acetate on the determinants of cardiac excitability in sheep Purkinje fibers. J Cardiovasc Electrophysiol 1996; 7:1172-1182.
26. Starmer CF, Lastra AA, Nesterenko VV, et al. Proarrhythmic response to sodium channel blockade: Theoretical model on numerical experiments. Circulation 1991; 84:1364-1377.
27. Cabo C, Pertsov AM, Baxter WT, et al. Wave-front curvature as a cause of slow conduction and block in isolated cardiac muscle. Circ Res 1994; 75: 1014-1028.
28. Ranger S, Talajic M, Lemery R, et al. Amplification of flecainide-induced ventricular conduction slowing by exercise: A potentially significant clinical consequence of use-dependent sodium channel blockade. Circulation 1989; 79:1000-1006.
29. Peters RW, Mitchell LB, Brooks MM, et al. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the cardiac arrhythmia suppression trial (CAST). J Am Coll Cardiol 1994; 23:283-289
30. Turton M, Deegan T. Circadian variations of plasma catecholamine, cortisol, and immunoreactive insulin concentrations in supine subjects. Clin Chim Acta 1974; 55:389-397.
31. + increase and noradrenaline release as possible causes of early arrhythmias following acute coronary artery occlusion in pigs. J Mol Cell Cardiol 1980; 12:579-593.
32. Lammerant J, DeHert P, DeSchryver C. Direct release of catecholamine into the left heart chambers: The enhancing effect of acute coronary occlusion. Arch Int Pharmacodyn 1966; 163: 219-229.
33. Wollenbeger AM, Shahab L. Anoxia-induced release of noradrenaline from the isolated perfused heart. Nature 1965; 207:88-91.
34. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 1989; 80:1571-1579.
35. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol 1994; 74:674-680.
36. max. PACE 1991; 14:726.
37. Lee HC, Matsuda JJ, Reynertson SI, et al. Reversal of lidocaine effects on sodium currents by isoproterenol in rabbit hearts and heart cells. J Clin Invest 1993; 91:693-701.
38. Newman DM, Herre JM, Chin MC, et al. Effects of sympathetic tone and action potential duration on in vivo use-dependence. Circulation 1988; 78(Suppl. II):II-146.
39. Epstein LM, Chin MC, Scheinman MM, et al. The action of isoproterenol on the use-dependent effect of amiodarone. J Am Coll Cardiol 1990; 15: 234A.
40. Avitall B, Hare J, Tchou P, et al. Flecainide toxicity: Reversal of drug effects by isoproterenol infusion. J Cardiovasc Electrophysiol 1991; 2: 431-440.
41. Morady F, Kou WH, Kadish AH, et al. Antagonism of quinidine's electrophysiologic effects by epinephrine in patients with ventricular tachycardia. J Am Coll Cardiol 1988; 12:388-394.
42. Calkins H, Sousa J, El-Atassi R, et al. Reversal of antiarrhythmic drug effects by epinephrine: Quinidine versus amiodarone. J Am Coll Cardiol 1992; 19:347-352.
43. Sager P, Ahmed R, Behboodikhah M, et al. Differential electrophysiologic actions of beta-adrenergic stimulation on sotalol and quinidine in humans. J Am Coll Cardiol 1993; 21:245A.
44. Jazayeri MR, Van Wyke G, Avitall B, et al. Isoproterenol reversal of antiarrhythmic effects in patients with inducible sustained ventricular tachyarrhythmias. J Am Coll Cardiol 1989; 14:705-711.
45. Niazi I, Naccarelli G, Dougherty A, et al. Treatment of atrioventricular node reentrant tachycardia with encainide: Reversal of drug effect with isoproterenol. J Am Coll Cardiol 1989; 13:904-910.
46. Manolis AS, Estes NAM III. Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. Am J Cardiol 1989; 64:194-198.
47. Dubuc M, Kus T, Fromer M, et al. Reversibility of the electrophysiologic effects of antiarrhythmic drugs by isoproterenol in patients with paroxysmal supraventricular tachycardia (PSVT). Circulation 1987; 76:IV-69.
48. Markel ML, Miles WM, Luck JC, et al. Differential effects of isoproterenol on sustained ventricular tachycardia before and during procainamide and quinidine antiarrhythmic drug therapy. Circulation 1993; 87:783-792.
49. Kass RS, Wiegers SE. The ionic basis of concentration-related effects of noradrenaline on the action potential of calf cardiac Purkinje fibers. J Physiol (Lond) 1982; 322:541-558.
50. Walsh KB, Begenisich TB, Kass RS. β-adrenergic modulation of cardiac ion channels: Differential temperature sensitivity of potassium and calcium currents. J Gen Physiol 1989; 93:841-854.
51. Matsuda JJ, Lee H, Shibata EF. Enhancement of rabbit cardiac sodium channels by β-adrenergic stimulation. Circ Res 1992; 70:199-207.
52. ++i. Circulation 1990; 82 (Suppl. III):111-522.
53. Schubert B, Van Dongen AMJ, Kirsch GE, et al. β-adrenergic inhibition of cardiac sodium channels by dual G-protein pathways. Science 1989; 245: 516-519.
54. + currents by isoproterenol. Am J Physiol 1990; 258:H977-H982.
55. Ono K, Kiyosue T, Arita M. Isoproterenol, DB-cAMP, and forskolin inhibit cardiac sodium current. Am J Physiol 1989; 256:C1131-C1137.
56. Gintant GA, Liu DW. β-adrenergic modulation of fast inward sodium current in canine myocardium: Syncytial preparations versus isolated myocytes. Circ Res 1992; 70:844-850.
57. + channel blockade by cyclic AMP and other 6-aminopurines in neonatal rat heart. J Membrane Biol 1991; 119:163-170.
58. Arita M, Kiyosue T, Aomine M, et al. Nature of "residual fast channel" dependent action potentials and slow conduction in guinea pig ventricular muscle and its modification by isoproterenol. Am J Cardiol 1983; 51:1433-1440.
59. Hisatome I, Kiyosue T, Imanishi S, et al. Isoproterenol inhibits residual fast channel via stimulation of β-adrenoreceptors in guinea-pig ventricular muscle. J Mol Cell Cardiol 1985; 17:657-665.
60. +-system in ventricular muscle fibers. J Mol Cell Cardiol 1982; 14: 431-434.
61. Kirstein M, Eickhorn R, Langenfeld H, et al. Influence of β-adrenergic stimulation on the fast sodium current in the intact rat papillary muscle. Basic Res Cardiol 1991; 86:441-448.
62. Ono K, Fozzard HA, Hanck DA. Mechanism of cAMP-dependent modulation of cardiac sodium channel current kinetics. Circ Res 1993; 72: 807-815.
63. Sunami A, Fan Z, Nakamura F, et al. The catalytic subunit of cyclic AMP-dependent protein kinase directly inhibits sodium channel activities in guinea-pig ventricular myocytes. Pflugers Arch 1991; 419:415-417.
64. Sorbera LA, Morad M. Modulation of cardiac sodium channels by cAMP receptors on the myocyte surface. Science 1991; 253:1286-1289.
65. + channels expressed in a mammalian cell line and in ventricular myocytes by protein kinase C. Proc Natl Acad Sci USA 1994; 91:3289-3293.
66. Li M, West JW, Numann R, et al. Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase. Science 1993; 261:1439-1442.
67. Walton MK, Fozzard HA. Experimental study of the conducted action potential in cardiac Purkinje strands. Biophys J 1983; 44:1-8.
68. Packer DL, Grant AO, Strauss HC, et al. Characterization of concentration- and use-dependent effects of quinidine from conduction delay and declining conduction velocity in canine Purkinje fibers. J Clin Invest 1989; 83:2109-2119.
69. Munger T, Johnson S, Packer D. Voltage dependence of β-adrenergic modulation of conduction in the canine Purkinje fiber. Circ Res 1994; 75: 511-519.
70. ++ in the control of electrical coupling in heart fibers. Biochem et Biophys Acta 1986; 888:91-99.
71. De Mello WC. Modulation of junctional permeability. In WC De Millo (ed.): Cell-to-Cell Communication. New York, NY, Plenum Press, 1987, pp. 59-64.
72. De Mello WC. Effect of intracellular injection of cAMP on the electrical coupling of mammalian cardiac cells. Biochem Biophys Res Commun 1984; 119:1004-1007.
73. Burt JM, Spray DC. Inotropic agents modulate gap junctional conductance between cardiac myocytes. Am J Physiol 1988; 254:H1206-H1210.
74. Spray DC, Harris AL, Bennett MVL. Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol 1981; 77:77-93.
75. Hondeghem LM, Katzung BG. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochimica et Biophysica Acta 1977; 472:373-398.
76. Cragun KT, Johnson SB, Packer DL. Isoproterenol amplification of flecainide-induced conduction slowing in depolarized canine Purkinje fibers: Elucidation of flecainide proarrhythmia in CAST. J Am Coll Cardiol 1995; 25:284A.
77. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 reentry? Circulation 1993; 87:562-572.
78. Brugada J, Boersma L, Kirchhof C, et al. Double-wave reentry as a mechanism of acceleration of ventricular tachycardia. Circulation 1990; 81: 1633-1643.